A Sun City research laboratory analyzed blood samples for a study published Thursday in JAMA that found a measurable blood signal associated with advanced chronic traumatic encephalopathy, or CTE.
The finding could help researchers move toward detecting CTE-related brain changes while people are alive. It is not a clinically validated diagnostic test, is not approved by the Food and Drug Administration and is not available to the public.
The Nov. 19 study was led by Boston University and Banner Health researchers. Plasma samples were sent to the Michael T. Zuendel Family Biomarker Laboratory at Banner Sun Health Research Institute in Sun City and to Alamar Biosciences for analysis.
What the study found
The case series included 21 male former football players who had provided blood samples during life and later donated their brains for examination. Autopsies found CTE in 18 participants. Sixteen had high-stage disease, two had low-stage disease and three had no CTE.
Researchers measured a tau-protein fragment called eMTBR-tau. Median concentrations were 0.021 picograms per milliliter among participants with high-stage CTE, compared with 0.001 picograms per milliliter for both the low-stage and no-CTE groups.
The concentration also rose with the cumulative burden of tau tangles found across 11 brain regions. The association remained significant when researchers excluded five participants who also had intermediate or high Alzheimer disease-related brain changes.
Those results point to a potential marker for advanced CTE pathology. They do not establish a test that can reliably screen the general public or identify early disease.
Why the limits matter
The study used a small, selected group. Eighteen of the 21 participants had CTE, all were men, and only three formed the comparison group without the disease. The sample was drawn from people already participating in research and willing to donate their brains.
Ten samples were below the assay’s lower limit of quantification. That group included all three participants without CTE, both people with low-stage CTE and five people with stage III disease. The study therefore could not establish a clinically useful cutoff or show that the marker can find mild disease.
An accompanying JAMA editorial called the work preliminary and said larger, independent studies must determine whether the marker can distinguish CTE from other neurodegenerative diseases. Alzheimer disease and other conditions can produce overlapping tau-related changes.
CTE is associated with repeated head impacts and currently can be confirmed only by examining brain tissue after death. A reliable living-person biomarker could eventually help researchers select participants for clinical trials and test treatments, but validation across earlier disease stages and more representative populations is still required.
Banner Health’s study announcement says the work was supported by the National Institute of Neurological Disorders and Stroke and the National Institute on Aging. Banner advised people concerned about their brain health to seek evaluation from a clinician who specializes in neurodegenerative conditions.



Comments
Join the conversation. Keep comments relevant, civil and focused on the story.